Di Cui
崔迪
Di Cui is the founder and CEO of DiShi Medical (迪视医疗), a Chinese microsurgical robotics company developing high-precision ophthalmic surgical robots . The company's flagship product, "迪视微锋" (DigiSight/DiSight), is positioned as one of the highest-precision ophthalmic surgical robots globally . Under Cui's leadership, DiShi Medical completed Asia's first clinical application of ophthalmic robotics and has raised multiple funding rounds including Pre-A and Pre-A+ rounds led by Linear Capital . Cui holds a PhD and has nearly a decade of deep technical accumulation in microsurgery ; in 2024, he was named to Cyzone's "35 Under 35 Entrepreneurs Pioneer List" .
AI-generated — may contain errors, please verify.
Coverage
Linear Voice: 2025 in the Linear Capital Network
Those real and important moments.
"Digisight Medical" Closes Nearly 100 Million RMB Series A, Leading Microsurgical Robotics | Linear Portfolio
Accelerating clinical application and market expansion.
Linear Capital Partner Songyan Huang Makes Repeat Appearance on 36Kr's "36 Under 36" Investors List
Recently, 36Kr released its 2024 ["36under36" series rankings](https://mp.weixin.qq.com/s?__biz=Mzk0MDMyNDUxOQ==&mid=2247490968&idx=1&sn=027309e5c24b1eceda88d9ae5095a639&scene=21&
Linear Capital Partner Songyan Huang Retains Spot on Cyzone's "Under 40 Investors" List
This week, ChinaBang (创业邦) released its 2024 "Top Investors Under 40" list, evaluating nominees across three dimensions: **overall influence, investment performance, and exit performance**. Among the honorees, Linear Capital partner Songyan Huang made the list for the third consecutive year, following his selections in [2022](http://mp.weixin.qq.com/s?__biz=MzAwNTAyMDAyNQ==&mid=2652302
"DiSight Medical" Cui Di: Solving Pain Points in Fundus and Microsurgery with High-Precision Ophthalmic Surgical Robots | Linear Capital Portfolio Interview Series
In July 2023, Linear Capital portfolio company Hangzhou Disight Medical Biotechnology Co., Ltd. successfully performed a subretinal thrombolysis procedure for treating macular hemorrhage at Zhejiang Provincial People's Hospital using its "Disight MicroEdge" ophthalmic surgical robot — **the first such procedure in Asia**. The company achieved its clinical milestone just two years after founding, and completed [three rounds of financing](https://mp.weixin.qq.com/s/...) in 2023 alone.
Linear Capital Portfolio Company DigiSight Ophthalmic Surgery Robot Completes Asia's First Clinical Application of Ophthalmic Robotics
Recently, portfolio company of Linear Capital **Hangzhou Disight Medical Biotechnology Co., Ltd.** successfully completed its first retinal sub-thrombolysis surgery for treating macular hemorrhage using its **"Disight MicroEdge"** ophthalmic surgical robot at Zhejiang Provincial People's Hospital. The procedure was safe and smooth, the patient recovered well, and has since been discharged in stable condition. This marks the first clinical application of an ophthalmic robot in Asia, representing a major technological advance for the entire field of ophthalmic microsurgery.
Linear Capital's Pre-A lead portfolio company **DigiSight Medical** has closed a multi-million-yuan Pre-A+ round, with existing investor Linear Capital continuing to back the company.
Accelerating clinical trials and R&D for ophthalmic and microsurgical robotic products.
Microsurgical robotics platform "Digisight Medical" raises tens of millions of RMB in Pre-A funding led by Linear Capital | Linear News
Dongli Network has learned that **Dishi Medical recently completed a Pre-A round of financing worth tens of millions of RMB, led by Linear Capital with Hillhouse as a co-investor.** The funds from this round will be used primarily to accelerate NMPA Class III medical device registration for its ophthalmic surgical robot, advance R&D on product lines including microsurgical robots, and expand the team.
